Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria